Ismo Retard Tablet ER contains Isosorbide Mononitrate 40 mg, a long-acting nitrate used primarily for the prevention and management of angina pectoris due to coronary artery disease. Isosorbide Mononitrate acts as a vasodilator by releasing nitric oxide, which relaxes vascular smooth muscle, leading to the dilation of peripheral veins and arteries. This results in reduced myocardial oxygen demand by decreasing preload and afterload, thereby alleviating anginal symptoms. The extended-release formulation ensures a sustained therapeutic effect, maintaining stable plasma concentrations over an extended period and minimizing the frequency of dosing. Ismo Retard Tablet ER is indicated for prophylactic treatment rather than acute angina attacks. It should be administered orally, typically once daily, preferably in the morning to reduce the risk of tolerance development. Common side effects may include headache, dizziness, hypotension, and flushing. Caution is advised in patients with hypotension, severe anemia, or those concurrently using phosphodiesterase inhibitors due to the risk of severe hypotension. Regular monitoring and adherence to prescribed dosing schedules are essential to optimize therapeutic outcomes and minimize adverse effects. Ismo Retard Tablet ER should be used under medical supervision with consideration of individual patient risk factors.